Eileen Walther, 66, is not your typical pet owner. While most people may seek the company of a furry, four-legged friend Walther cares for an entirely different type of animal: bees. For someone who has had to face two separate cancer diagnoses, Walther says her bees provide a great escape — and have helped her … Continued
Mantle cell lymphoma is a rare, often aggressive form of non-Hodgkin lymphoma (NHL), a cancer that involves white blood cells known as lymphocytes, which help protect the body from disease. It is named for its origins in the mantle zone — a ring of cells within the lymph nodes where B cells (a type of … Continued
Steve Kelley is the quintessential glass half-full guy. Still, he realizes his reaction to learning he had an extremely rare cancer known as central nervous system (CNS) lymphoma may seem unusual. A few weeks after his June 2018 diagnosis, Kelley, then 64, gathered his family and friends together. He didn’t want to focus negatively on … Continued
Jerry Jalbert is always up for new adventures. He did not expect that non-Hodgkin lymphoma (NHL) would be one of them, but with the help of CAR T-cell therapy that keeps his cancer at bay, the 73-year-old professional photographer-turned-baker-turned-forest checkpoint operator is continuing to enjoy life’s many journeys alongside his wife, Ethel. “We are not … Continued
In May 2018, Tyler Goodwin underwent CAR T-cell therapy for follicular non-Hodgkin lymphoma (NHL). While he was having preparatory chemotherapy for the procedure, a surprise visitor to his hospital bedside provided a powerful reminder of why this promising new cancer treatment was so important to him. “It was my daughter Theresa, all made up for … Continued
A troublesome cough led Patty Reid on a nine-months-long medical odyssey that resulted in a diagnosis of non-Hodgkin lymphoma (NHL). Just as the then-60-year-old was preparing for a stem cell transplant in late 2016, a new research discovery prompted her doctors to change the type of transplant Reid received—greatly lessening her risk for another cancer … Continued
There was a time when Georgette Hannoush couldn’t imagine a bright future. In a four-year span, the mother of four—including triplets—was diagnosed with two different types of cancer. But because of her team at Dana-Farber Cancer Institute, Hannoush has been in remission for more than three years—and she credits her faith and the people she … Continued
In early 2018, Sandra Linberg received an infusion of CAR T cells only a few months after the therapy was approved for treating her type of cancer. After only a month, her lymphoma had completely disappeared – she was in a complete remission. “Those little warrior cells took care of it,” declared Linberg, who has continued … Continued
Cutaneous lymphoma is a rare subtype of non-Hodgkin lymphoma that starts in the skin.
During a “couples chemo” session, Kevin got down on one knee and popped the question to Tim, his partner of 37 years. They tied the knot in the Healing Garden at Dana-Farber.
One of the most exciting new cancer treatments, CAR T-cell therapy takes its complicated name, in part, from a fire-breathing monster in an ancient Greek myth. CAR is an acronym for “chimeric antigen receptor,” referring to genetically engineered molecules manufactured in a laboratory, inserted into the genetic material of immune T cells that have been … Continued
Medically reviewed by Ann S. LaCasce, MD, MMSc After a patient is diagnosed with lymphoma, doctors determine the stage of the disease — or how widespread the cancer is — and then come up with a treatment plan. As with most cancers, there are generally four different stages of lymphoma: I, II, III, and IV. … Continued
Charles “Chuck” Vanada has been looking forward to Thanksgiving with his family this year, but the non-Hodgkin lymphoma survivor has already experienced feelings of gratitude in 2017 more powerful – and in places more unexpected – than anything he could have imagined. In April, Vanada and his wife, Debbie, traveled from their Boston-area home to … Continued
A drug called Axicabtagene ciloleucel (KTE-C19) has become the first chimeric antigen receptor (CAR) T-cell therapy approved to treat a form of cancer in adults, the Food and Drug Administration (FDA) announced today. The decision means the drug, known as Yescarta, can now be used for some adults with refractory aggressive non-Hodgkin lymphoma (NHL). The FDA ruling in … Continued
Non-Hodgkin lymphoma is one of the two major subtypes of lymphoma, and about 72,000 people will be diagnosed with this cancer by the end of 2017, according to the American Cancer Society. There are more than 50 types of non-Hodgkin lymphoma – including B-cell and T-cell lymphomas, as well as fast-growing and slow-growing lymphomas. There … Continued
Non-Hodgkin lymphoma refers to any of a large group of cancers of the immune system that can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. It is one of the most common cancers in the United States, accounting for about 4 percent of all cancers, according to … Continued
Identical twins George and Greg Robinson have been inseparable for 57 years, from sharing a childhood bedroom and classes in school through dual Air Force stints and careers in the airline industry. Today, back in their native Cambridge, Mass., they live just a block apart and still talk several times daily. But there is one … Continued
CAR T-cell therapy is a form of immunotherapy in which patients’ T cells are modified to become better at tracking down and destroying tumor cells. CAR T cells are made by extracting thousands of a patient’s T cells, sending them to a lab where they’re outfitted with genes and proteins that improve their cancer-fighting prowess, … Continued
Elizabeth Larcom has six children, but it’s the youngest that she calls her “miracle baby” – and with good reason. In August 1997, the Army moved the Larcom family to Alaska with five kids under 12 and mom Elizabeth pregnant with the sixth. Soon after, husband and dad, Chuck, left for Army training in Louisiana. … Continued
The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy. The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is … Continued
